Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/86493
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer
Author: Zinonos, I.
Luo, K.
Labrinidis, A.
Liapis, V.
Hay, S.
Panagopoulos, V.
Denichilo, M.
Ko, C.
Yue, G.
Lau, C.
Ingman, W.
Ponomarev, V.
Atkins, G.
Findlay, D.
Zannettino, A.
Evdokiou, A.
Citation: International Journal of Oncology, 2014; 45(2):532-540
Publisher: Spandidos Publications
Issue Date: 2014
ISSN: 1019-6439
1791-2423
Statement of
Responsibility: 
Irene Zinonos, Ke-Wang Luo, Agatha Labrinidis, Vasilios Liapis, Shelley Hay, Vasilios Panagopoulos, Mark Denichilo, Chun-Hay Ko, Grace Gar-Lee Yue, Clara Bik-San Lau, Wendy Ingman, Vladimir Ponomarev, Gerald J. Atkins, David M. Findlay, Andrew C.W. Zannettino, Andreas Evdokiou
Abstract: Osteoprotegerin (OPG) is a secreted member of the TNF receptor superfamily, which binds to the receptor activator of nuclear factor κB ligand (RANKL) and inhibits osteoclast activity and bone resorption. Systemic administration of recombinant OPG was previously shown to inhibit tumor growth in bone and to prevent cancer-induced osteolysis. In this study, we examined the effect of OPG, when produced locally by breast cancer cells located within bone, using a mouse model of osteolytic breast cancer. MDA-MB-231-TXSA breast cancer cells, tagged with a luciferase reporter gene construct and engineered to overexpress full-length human OPG, were transplanted directly into the tibial marrow cavity of nude mice. Overexpression of OPG by breast cancer cells protected the bone from breast cancer-induced osteolysis and diminished intra-osseous tumor growth but had no effect on extra-skeletal tumor growth. This effect was associated with a significant reduction in the number of osteoclasts that lined the bone surface, resulting in a net increase in bone volume. Despite limiting breast cancer-mediated bone loss, OPG overexpression resulted in a significant increase in the incidence of pulmonary metastasis. Our results demonstrate that inhibition of osteoclastic bone resorption by OPG when secreted locally by tumors in bone may affect the behaviour of cancer cells within the bone microenvironment and their likelihood of spreading and establishing metastasis elsewhere in the body.
Keywords: Osteoprotegerin; bone metastasis; bone resorption; anti-resorptive agents; bisphosphonates
Rights: © Spandidos Publications 2014. All rights reserved.
RMID: 0030010278
DOI: 10.3892/ijo.2014.2468
Grant ID: http://purl.org/au-research/grants/nhmrc/627015
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.